Incidence and mortality for sex-unspecific cancers are higher among men, a fact that is largely unexplained 1,2 . Furthermore, age-related loss of chromosome Y (LOY) is frequent in normal hematopoietic cells 3, 4 , but the phenotypic consequences of LOY have been elusive [5] [6] [7] [8] [9] [10] . From analysis of 1,153 elderly men, we report that LOY in peripheral blood was associated with risks of all-cause mortality (hazards ratio (HR) = 1.91, 95% confidence interval (CI) = 1.17-3.13; 637 events) and non-hematological cancer mortality (HR = 3.62, 95% CI = 1.56-8.41; 132 events). LOY affected at least 8.2% of the subjects in this cohort, and median survival times among men with LOY were 5.5 years shorter. Association of LOY with risk of all-cause mortality was validated in an independent cohort (HR = 3.66) in which 20.5% of subjects showed LOY. These results illustrate the impact of post-zygotic mosaicism on disease risk, could explain why males are more frequently affected by cancer and suggest that chromosome Y is important in processes beyond sex determination. LOY in blood could become a predictive biomarker of male carcinogenesis.
Peripheral blood DNA from 1,153 participants of the Uppsala Longitudinal Study of Adult Men (ULSAM) was genotyped using the high-resolution 2.5M HumanOmni SNP BeadChip from Illumina. The population-based ULSAM cohort has extensive phenotypic information available on naturally aging men who were clinically followed for >40 years. We studied DNA sampled in an age window of 70.7-83.6 years. Scoring of structural genetic variants was focused on post-zygotically acquired changes such as deletions, copy number-neutral loss of heterozygosity (CNNLOH, also called acquired uniparental disomy, aUPD) and gains, as described previously [11] [12] [13] , with a minimum size of 2 Mb. Twelve subjects had a history of hematological malignancy before sampling, and these individuals were analyzed separately to avoid mixed analyses of normal blood and malignant clones ( Supplementary Figs. 1 and 2 ). In the remaining 1,141 participants, we uncovered 40 autosomal somatic structural variants of ≥2 Mb in length occurring in 37 subjects (3.2%), including 13 deletions, 16 CNNLOH events and 11 gains ( Fig. 1 and Supplementary Table 1) .
Strikingly, the most frequent somatic variant was LOY ( Figs. 1  and 2 ). The degree of LOY was calculated for each subject from the median log R ratio values (measuring copy number) for approximately 2,560 probes in the male-specific region of chromosome Y (mLRR-Y) and suggested considerable interindividual differences in the proportion of cells with nullisomy Y. A conservative estimate of the frequency of LOY in the ULSAM cohort of 8.2% (93/1,141) was based on the lowest value (-0.139) in a simulated distribution of experimental variation in mLRR-Y values (Fig. 2) . At this threshold, ≥18% of cells in affected participants would be expected to have nullisomy Y. To calculate the fraction of cells affected by nullisomy Y, we implemented a new approach using B allele frequency (BAF) values for pseudoautosomal region 1 (PAR1) on chromosomes X and Y from SNP array data (explained in Supplementary Fig. 3 ).
Aberrations detected with Illumina 2.5M HumanOmni SNP arrays were validated using low-coverage (~5×) whole-genome next-generation sequencing, performed for 100 random participants. Of the 93 subjects with LOY in ≥18% of cells, sequencing was performed for 6, and all these cases of LOY were validated ( Supplementary Figs. 4-7) . Of the 37 subjects with autosomal events of ≥2 Mb in length, we performed whole-genome and/or whole-exome next-generation sequencing for 4 subjects with deletions, and all were validated ( Supplementary  Figs. 8-10) . Moreover, the SNP array data suggested that some participants could have a gain of chromosome Y (GOY) (Fig. 2) . However, next-generation sequencing did not confirm these observations in the three suspected cases of GOY that were sequenced ( Supplementary Fig. 11 ). In summary, for autosomes and sex chromosomes in 1,141 subjects, we scored 133 somatic structural variants Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer in 128 men (11.2%). Furthermore, participants with LOY did not show a difference in the frequency of autosomal structural variants compared to the rest of the cohort (data not shown), and we did not observe evidence of region-specific deletions on chromosome Y (Supplementary Figs. 5-7) .
The effects of the identified structural variants on all-cause mortality, cancer-related mortality and non-cancer-related mortality were examined by Cox proportional hazards regression using the R package Survival. In survival analyses, we studied 982 participants free from cancer diagnosis before sampling (Supplementary Fig. 1 ), and survival was adjusted for nine potential confounders: age, hypertension, exercise, smoking, diabetes, body mass index (BMI), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and ancestry ( Table 1 and Supplementary Table 2 ). Study entry was the date of DNA sampling, age was used as a timeline and the median follow-up time was 8.7 years (range of 0-20.2 years). Structural genetic variants were analyzed in three categories. LOY was analyzed separately as a continuous variable (mLRR-Y). Other deletions and CNNLOH were grouped as autosomal loss of heterozygosity (LOH) variants, reflecting their similar biological effects 14 . The third category included autosomal gains. In primary survival analysis using the continuous estimator of LOY (mLRR-Y), men with a higher degree of LOY had increased risk of all-cause mortality (HR = 2.13, P = 0.029; Table 1 ). Further tests with the continuous estimator showed that LOY was a key risk factor for cancer-related mortality in the ULSAM cohort (HR = 3.76, P = 0.022; Table 1 ). However, LOY was not significantly associated with non-cancer-related mortality (P = 0.245; Supplementary Fig. 1 ).
To plot the above results and to perform further exploratory tests, we scored participants on the basis of a defined threshold of mLRR-Y. Specifically, individuals with mLRR-Y of ≤-0.4 ( Fig. 2) were scored as 1, and other subjects were scored as 0 (explained in Supplementary  Fig. 12 ). These tests confirmed the effect of LOY on risk for all-cause mortality (HR = 1.91, P = 0.010; Fig. 3a ) and showed that median survival times (with 50% probability of survival) in the group of men with LOY were 5.5 years shorter than for controls, representing half the survival time. The effect of LOY on risk of cancer-related mortality was also confirmed (HR = 3.29, P = 0.003; Fig. 3b ). We further found that risk for non-hematological cancer mortality was clearly associated with LOY (HR = 3.62, P = 0.003; Fig. 3c ). Moreover, risk of any cancer diagnosis, as well as risk of diagnosis with non-hematological cancer, was higher in participants with mLRR-Y of ≤−0.4 (HR = 2.47, P = 0.014 and HR = 2.68, P = 0.008, respectively) ( Supplementary Fig. 1 ). 
We could not perform a valid test of the effect of LOY on the risk of mortality from hematological malignancies because only one participant scored with LOY died from such a cancer.
We replicated the result of LOY association with increased risk of all-cause mortality in an independent cohort of slightly younger males (age range of 69.8-70.7 years) from the PIVUS (Prospective Investigation of the Vasculature in Uppsala Seniors) study. The longest and median follow-up times were >10 and 7.0 years, respectively. Blood DNA from 488 men was genotyped using the Illumina OmniExpress chip, and we scored aberrations on autosomes and sex chromosomes as described for the ULSAM cohort. The experimental noise from SNP genotyping was considerably lower in the PIVUS cohort, and, in scoring of LOY, 100 males (20.5%) had LOY in ≥13% of nucleated blood cells (Supplementary Fig. 13 ). Furthermore, we scored 12 autosomal somatic aberrations of ≥2 Mb in length in the PIVUS cohort, including 6 gains, 3 deletions and 3 CNNLOH events (Supplementary Table 3 ). Cox proportional hazards regression with the same nine confounders was performed in the PIVUS cohort as described for the ULSAM cohort (Supplementary Table 4) . Analysis using the continuous estimator of LOY (mLRR-Y) confirmed that men with a higher degree of LOY had increased risk of all-cause mortality (HR = 5.24, P = 0.022,). Furthermore, after subjects were scored as 1 or 0 on the basis of LOY status (Supplementary Fig. 14) , survival analysis showed that men with LOY had higher risk for all-cause mortality (HR = 3.66, 95% CI = 1.27-10.54; P = 0.016; number of events = 59). In summary, the results from the ULSAM cohort showing that LOY increased the risk for all-cause mortality were validated in the independent PIVUS cohort. It has recently been reported that somatic structural variants of autosomes in blood cells are connected with risk of hematological cancers, resulting in 5.5-to 35.4-fold higher risk 12, 13, 15 . Thus, the question of whether LOY is also connected with increased risk of hematological malignancies needs to be further investigated. Furthermore, Jacobs et al. 12 found that autosomal somatic aberrations were more frequent in subjects with solid tumors (OR = 1.25), which is in agreement with the results for chromosome Y reported here.
Chromosome Y is recognized for its role in sex determination and normal sperm production, but it has long been considered to be a genetic wasteland, and, for several reasons, its characterization has lagged behind that of the rest of the genome. However, recent studies in humans and in a few other primates have shown that human chromosome Y contains a large number of genes 16, 17 , indicating that it is not a gene desert. Furthermore, variation on chromosome Y has been associated with the expression of hundreds of autosomal and X-linked genes in Drosophila melanogaster 18, 19 . Our results support the notion that human chromosome Y is important in biological processes beyond sex determination and reproduction. It has been known for more than half a century that elderly males frequently lose chromosome Y in normal hematopoietic cells 3, 4 . The clinical consequences of this aneuploidy have been unclear, and the prevailing consensus suggests that this aberration should be considered to be phenotypically neutral and related to normal aging [5] [6] [7] [8] [9] [10] . Furthermore, nullisomy Y has also been shown to occur in human cancer cells, and the literature provides a list of up to 20 different malignancies with LOY in combination with numerous other structural aberrations of the genome. Employing various methods, these studies showed that LOY often occurs at high frequency in tumors [20] [21] [22] [23] . Recent comprehensive analysis showed that chromosome Y is one of the most commonly deleted chromosomes in the human cancer genomes 24 . Moreover, azoospermia is associated with higher cancer risk 25 , suggesting a connection between chromosome Y and cancer. Also, reintroduction of chromosome Y into a prostate cancer cell line suppresses its tumorigenicity in nude mice 26 . In summary, the above findings indicate that chromosome Y has a role in tumor suppression, and our results on expanding cell clones with LOY are in agreement with this hypothesis. Previously published data have shown that clonal expansions are common among the elderly, as a result of autosomal structural aberrations 11, 12, 14, 15 . We examined the dynamics of changes in the proportion of cells with LOY by longitudinal analyses of five ULSAM subjects with data collected at two time points 6-14 years (a-c) Impact of LOY on all-cause mortality (a), cancer mortality (b) and mortality from nonhematological cancers (c) in 982 men with no history of cancer before sampling. The HR, 95% CI, number of events and P value are shown for each model. Results are derived from Cox proportional hazards regression models, with subjects classified into groups 1 and 0 on the basis of their level of LOY. Individuals in the affected group (red curves) had LOY in ≥35% of nucleated blood cells (Fig. 2) . npg l e t t e r s apart (Fig. 4) . Longitudinal LOY analyses in these subjects showed progressive accumulation of cells containing LOY over time. All five subjects had cancer diagnoses and a high percentage of cells with LOY, ranging from 41-87%. These observations indicate a need for further longitudinal analyses of larger numbers of subjects, aiming at better characterization of the critical level of LOY mosaicism in blood that is connected with cancer risk. One of our most noteworthy findings is that men with LOY in peripheral blood are at risk of cancer outside the hematopoietic system (Fig. 3) . These results could be explained by two hypotheses that are not mutually exclusive. First, a normal feature of the immune system is immune surveillance, which suppresses tumor development in other tissues 27 . In participants with a high proportion of leukocytes with LOY, this normal function could be disturbed, leading to higher cancer risk. This explanation is supported by a higher frequency of cancer in individuals with a history of treatment with immunosuppressive drugs 28, 29 . The second hypothesis is that LOY also occurs in additional tissues in parallel with the chromosome Y aneuploidy in blood, stimulating the neoplastic proliferation of cancer progenitors outside the hematopoietic system. This hypothesis is in agreement with the briefly described frequent LOY observed in a wide range of cancers. We investigated the spectrum of cancer diagnoses in men scored with LOY in comparison to the rest of the cohort, finding no apparent differences (Supplementary Fig. 15) . Regardless of the mechanism(s) underlying increased cancer risk in men with LOY, our results demonstrate the importance of post-zygotic aberrations, acquired during lifetime variation in normal cells, for the risk of cancer development. As mentioned, men have higher incidence and mortality rates for most sex-unspecific cancers, a fact that has largely been unexplained by known risk factors 1,2 . Thus, our findings could help in explaining why males are more frequently affected by cancer. We further anticipate that extension of our study with respect to post-zygotic LOY in blood cells and possibly also in other tissues could in the future become a useful predictive biomarker of male carcinogenesis. 
URLs. ULSAM (Uppsala Longitudinal

